Zurich Cantonal Bank
YMAB

Zurich Cantonal Bank’s Y-mAbs Therapeutics YMAB Stock Holding History

Zurich Cantonal Bank’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,324
Closed -$26K – 2686
2024
Q4 		$26K Hold
3,324
– – ﹤0.01% 2586
2024
Q3 		$43.7K Buy
+3,324
New +$42.1K ﹤0.01% 2566
2023
Q1 		– Sell
-1,694
Closed -$8.27K – 2879
2022
Q4 		$8.27K Sell
1,694
-4,819
-74% -$35K ﹤0.01% 2814
2022
Q3 		$94K Hold
6,513
– – ﹤0.01% 2279
2022
Q2 		$99K Buy
6,513
+4,645
+249% +$54.2K ﹤0.01% 2257
2022
Q1 		$22K Hold
1,868
– – ﹤0.01% 2660
2021
Q4 		$30K Hold
1,868
– – ﹤0.01% 2825
2021
Q3 		$53K Buy
+1,868
New +$58.9K ﹤0.01% 2596
2021
Q1 		– Sell
-1,868
Closed -$92K – 2657
2020
Q4 		$92K Hold
1,868
– – ﹤0.01% 2247
2020
Q3 		$72K Buy
1,868
+1,197
+178% +$47.6K ﹤0.01% 2128
2020
Q2 		$29K Buy
+671
New +$25.4K ﹤0.01% 2376

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Zurich Cantonal Bank's YMAB Position: Q1 2025 in Review

Zurich Cantonal Bank sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 3,324 shares — an estimated $26K sold.

Zurich Cantonal Bank first reported a position in YMAB in Q2 2020 and held it in 11 quarters. The position peaked at $99K in Q2 2022. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Zurich Cantonal Bank reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 3,324 Y-mAbs Therapeutics shares in Q1 2025, an estimated $26K.
  • Zurich Cantonal Bank first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 11 quarters.
  • Zurich Cantonal Bank's Y-mAbs Therapeutics position peaked at $99K in Q2 2022.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Zurich Cantonal Bank's 13F filing for Q1 2025, filed 7 May 2025.